Medtronic wins CE Mark for Visia AF single-chamber ICDs

Medtronic (NYSE:MDT) said today that it won CE Mark approval in the European Union for its Visia AF and Visia AF MRI SureScan single-chamber implantable cardiac defibrillators.

The Visia devices are designed to detect incidences of atrial fibrillation using an algorithm, Fridley, Minn.-based Medtronic said.

“Medtronic is committed to continuing to develop a wide range of technologies to help patients with AF,” tachycardia general manager Dr. Marshall Stanton said in prepared remarks. “With devices like the Visia AF ICDs and the Reveal Linq insertable cardiac monitor, which detects and monitors abnormal heart rhythms for up to 3 years, we aim to increase AF detection and enable physicians to manage a patient’s risk for strokes and heart failure.”

The Visia devices also use an algorithm called SmartShock 2.0 that’s designed to reduce the amount of unnecessary shocks by distinguishing between dangerous and harmless cardiac rhythms, Medtronic said.

The post Medtronic wins CE Mark for Visia AF single-chamber ICDs appeared first on MassDevice.

from MassDevice http://ift.tt/1W3QNAR